PTC Therapeutics, Inc. (PTCT): EBITDA
$905.75M
Year ended 2025-12-31
$180.90M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $905.75M | n/m | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | -$226.91M | n/m | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | -$202.91M | n/m | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | -$318.57M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | -$310.31M | n/m | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | -$388.28M | n/m | 2023-02-21, From 2020-01-01 |
| 2019-12-31 | -$208.98M | n/m | 2022-02-22, From 2019-01-01 |
| 2018-12-31 | -$89.60M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$46.61M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | -$128.77M | n/m | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | -$164.25M | n/a | 2018-03-06, From 2015-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $905.75M | n/m |
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $245.91M | +57.6% |
| Alkermes plc. (ALKS) | 2025-12-31 | $281.12M | -37.4% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | -$655.26M | n/m |
| Indivior Pharmaceuticals, Inc. (INDV) | 2025-12-31 | $272.00M | +403.7% |
| Prestige Consumer Healthcare Inc. (PBH) | 2026-03-31 | $340.68M | -7.2% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | -$298.59M | n/m |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $1.58B | +8.9% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $489.04M | -15.8% |
Compare PTCT, PAHC, ALKS, SRPT side by side · Screen every company in Pharmaceutical Preparations ↗